Carl Dambkowski - 02 Jun 2026 Form 4 Insider Report for Oruka Therapeutics, Inc. (ORKA)

Reporting relationship: Director
Issuer ticker: ORKA
Reported as of: 02 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2026, 16:52:47 UTC
Prior SEC filing: 22 May 2026
Next SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Paul Quinlan, as attorney-in-fact for Carl Dambkowski

Key filing fact

Carl Dambkowski filed Form 4 for Oruka Therapeutics, Inc. (ORKA) on 03 Jun 2026.

Key facts

This page summarizes Carl Dambkowski's Form 4 filing for Oruka Therapeutics, Inc. (ORKA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2026, 16:52.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001983476 Primary reporting owner

Relationship: Director
Address: C/O ORUKA THERAPEUTICS, INC., 855 OAK GROVE AVE., SUITE 100, MENLO PARK
Signature: /s/ Paul Quinlan, as attorney-in-fact for Carl Dambkowski
Signature date: 03 Jun 2026

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ORKA transaction Derivative

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.